APS 2010

APS 2010

Low Back Pain: Evaluation, Management, and Prognosis

Low back pain is one of the top 10 most common reasons for doctor office visits in the United States; approximately 80% of adults seek care at some time for acute low back pain. The differential diagnosis for low back pain and the importance of identifying clinical red and yellow flags during evaluation was presented at the 29th Annual Scientific Meeting of the American Pain Society.

Preventing Inappropriate Opioid Use with REMS (Risk Evaluation and Mitigation Strategy)

Appropriate patient selection for opioid use is critical to ensuring patient safety and minimizing the risks associated with opioid use. Healthcare professionals should therefore understand not only their patients’ needs but also the concept of Risk Evaluation and Mitigation Strategy (REMS), which can help prevent inappropriate opioid use.

Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended-Release vs Oxycodone Controlled-Release Due to Adverse Events

Tapentadol extended-release (ER), an investigational drug, was associated with better gastrointestinal tolerability in elderly patients with moderate-to-severe chronic pain, with fewer discontinuing the study due to treatment-emergent adverse events (TEAEs) than oxycodone controlled-release (CR), investigators concluded in a presentation during the 29th Annual Scientific Meeting of the American Pain Society.

Transmucosal, Oral Opioids Found to be Concordant for Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain

Determining an effective opioid dose for chronic pain in patients who become opioid tolerant can be challenging. In fact, effective dosing of a rapid-onset transmucosal opioid for breakthrough pain is not related to the around-the-clock dose, studies have shown. However, few data exist on the effective dose of the more traditional, short-acting oral opioids, according a study presented at the 29th Annual Scientific Meeting of the American Pain Society.
.